# Clinical Study of Cardiomyopeptidin on Postoperative Ischemia-reperfusion Injury in Patients With Primary PCI

> **NCT03958422** · PHASE4 · UNKNOWN · sponsor: **Dalian Zhen-Ao Bio-Tech Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Survival Myocardial Area After Acute Myocardial Death
- Left Ventricular Ejection Fraction

## Interventions

- **DRUG:** cardiomyopeptidin

## Key facts

- **NCT ID:** NCT03958422
- **Lead sponsor:** Dalian Zhen-Ao Bio-Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2019-11-30
- **Final completion:** 2020-01-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2019-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03958422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03958422, "Clinical Study of Cardiomyopeptidin on Postoperative Ischemia-reperfusion Injury in Patients With Primary PCI". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03958422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*